Dr Kieran Docherty

  • Clinical Lecturer (Cardiovascular & Metabolic Health)

email: Kieran.Docherty@glasgow.ac.uk

BHF Cardiovascular Research Centre, 126 University Place, Glasgow, G12 8TA

ORCID iDhttps://orcid.org/0000-0002-5446-9969

Biography

Kieran Docherty studied medicine at the University of Glasgow from 2005-2011. He is a Cardiology Specialist Registrar in the West of Scotland Deanery and is currently a Clinical Research Fellow at the Institute of Cardiovascular and Medical Sciences at the University of Glasgow. He is undertaking a PhD under the supervision of Professor John McMurray and Professor Mark Petrie examining the effects of neprilysin inhibition on left ventricular remodelling. 

Research interests

  • Heart failure
  • myocardial infarction
  • epidemiology
  • clinical trials

Publications

List by: Type | Date

Jump to: 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013
Number of items: 72.

2022

Vaduganathan, M. et al. (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400(10354), pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5) (PMID:36041474)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (Early Online Publication)

Docherty, K. F. et al. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (Early Online Publication)

Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)

Lee, M. M. Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Lewis, G. D. et al. (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction. JAMA: Journal of the American Medical Association, 328(3), pp. 259-269. (doi: 10.1001/jama.2022.11016) (PMID:35852527)

Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)

Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, (doi: 10.1002/ehf2.13731) (PMID:35799450) (Early Online Publication)

McDowell, K. and Docherty, K. F. (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)

McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)

McMurray, J. J.V. and Docherty, K. F. (2022) Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45(S1), S26-S30. (doi: 10.1002/clc.23847)

Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Jhund, P. S. , Docherty, K. F. and McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)

Lewis, G. D. et al. (2022) Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF. Circulation: Heart Failure, 15(5), e008970. (doi: 10.1161/CIRCHEARTFAILURE.121.008970) (PMID:35236099)

Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)

Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004)

Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)

Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)

Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, (doi: 10.1093/rheumatology/keac072) (PMID:35136973) (Early Online Publication)

Docherty, K. F. and Petrie, M. C. (2022) Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108(4), pp. 312-320. (doi: 10.1136/heartjnl-2020-318658) (PMID:34127540)

Berg, D. D. et al. (2022) Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145(3), pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852) (PMID:34743554)

Rossing, P. et al. (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10(1), pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3) (PMID:34856173)

2021

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Lee, M. et al. (2021) Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. ESC Congress, 27-30 Aug 2021. (doi: 10.1093/eurheartj/ehab724.1043)

Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)

Petrie, M. C. , Lee, M. M.Y. and Docherty, K. F. (2021) Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), pp. 1256-1259. (doi: 10.1002/ejhf.2108) (PMID:33502794)

Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)

Espersen, C. et al. (2021) Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8(3), pp. 1784-1795. (doi: 10.1002/ehf2.13300)

Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)

Berg, D. D. et al. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)

Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)

Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)

Inzucchi, S. E. et al. (2021) Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44(2), pp. 586-594. (doi: 10.2337/dc20-1675) (PMID:33355302)

Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)

Docherty, K. F. and Vaduganathan, M. (2021) OUTSTEP‐HF: re‐evaluating the role of physical activity measures in drug and device development in heart failure. European Journal of Heart Failure, 23(1), pp. 136-139. (doi: 10.1002/ejhf.2106) (PMID:33480140)

McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)

2020

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)

Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)

McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)

Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)

Docherty, K. F. , Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)

Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)

Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)

Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)

Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)

Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)

2019

McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)

Docherty, K. F. and McMurray, J. J.V. (2019) PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115(13), e136-e139. (doi: 10.1093/cvr/cvz223) (PMID:31497841)

Platz, E. et al. (2019) Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7(10), pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008) (PMID:31582107)

Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)

McMurray, J. J.V. and Docherty, K. F. (2019) Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74(7), pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008) (PMID:31416534)

Dewan, P. , Docherty, K. F. and McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)

Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)

Docherty, K. F. and McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)

2018

Docherty, K. F. and Jhund, P. S. (2018) Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early? Heart, 104(22), pp. 1812-1813. (doi: 10.1136/heartjnl-2018-313371) (PMID:29760244)

Docherty, K. F. , Jhund, P. S. and McMurray, J. J.V. (2018) Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379(5), pp. 491-492. (doi: 10.1056/NEJMc1806519) (PMID:30070094)

2017

Docherty, K. F. , Campbell, R. T., Jhund, P. , Petrie, M. C. and McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)

2016

Wilson, M. R. , Docherty, K. F. and Gardner, R. S. (2016) Use of direct oral anticoagulants in thromboembolic disease. Prescriber, 27(8), pp. 15-22. (doi: 10.1002/psb.1487)

2014

Docherty, K. F. and Padmanabhan, S. (2014) Genomics and pharmacogenomics of lipid-lowering therapies. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Academic Press: London, pp. 715-746. ISBN 9780123868831 (doi: 10.1016/B978-0-12-386882-4.00031-1)

2013

Vuorio, A., Docherty, K.F. , Humphries, S.E., Kuoppala, J. and Kovanen, P.T. (2013) Statin treatment of children with familial hypercholesterolemia – trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis, 226(2), pp. 315-320. (doi: 10.1016/j.atherosclerosis.2012.10.032)

This list was generated on Thu Sep 29 07:56:22 2022 BST.
Number of items: 72.

Articles

Vaduganathan, M. et al. (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400(10354), pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5) (PMID:36041474)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (Early Online Publication)

Docherty, K. F. et al. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (Early Online Publication)

Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)

Lee, M. M. Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Lewis, G. D. et al. (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction. JAMA: Journal of the American Medical Association, 328(3), pp. 259-269. (doi: 10.1001/jama.2022.11016) (PMID:35852527)

Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)

Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, (doi: 10.1002/ehf2.13731) (PMID:35799450) (Early Online Publication)

McDowell, K. and Docherty, K. F. (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)

McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)

McMurray, J. J.V. and Docherty, K. F. (2022) Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45(S1), S26-S30. (doi: 10.1002/clc.23847)

Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Jhund, P. S. , Docherty, K. F. and McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)

Lewis, G. D. et al. (2022) Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF. Circulation: Heart Failure, 15(5), e008970. (doi: 10.1161/CIRCHEARTFAILURE.121.008970) (PMID:35236099)

Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)

Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004)

Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)

Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)

Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, (doi: 10.1093/rheumatology/keac072) (PMID:35136973) (Early Online Publication)

Docherty, K. F. and Petrie, M. C. (2022) Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108(4), pp. 312-320. (doi: 10.1136/heartjnl-2020-318658) (PMID:34127540)

Berg, D. D. et al. (2022) Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145(3), pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852) (PMID:34743554)

Rossing, P. et al. (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10(1), pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3) (PMID:34856173)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)

Petrie, M. C. , Lee, M. M.Y. and Docherty, K. F. (2021) Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), pp. 1256-1259. (doi: 10.1002/ejhf.2108) (PMID:33502794)

Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)

Espersen, C. et al. (2021) Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8(3), pp. 1784-1795. (doi: 10.1002/ehf2.13300)

Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)

Berg, D. D. et al. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)

Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)

Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)

Inzucchi, S. E. et al. (2021) Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44(2), pp. 586-594. (doi: 10.2337/dc20-1675) (PMID:33355302)

Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)

Docherty, K. F. and Vaduganathan, M. (2021) OUTSTEP‐HF: re‐evaluating the role of physical activity measures in drug and device development in heart failure. European Journal of Heart Failure, 23(1), pp. 136-139. (doi: 10.1002/ejhf.2106) (PMID:33480140)

McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)

Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)

McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)

Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)

Docherty, K. F. , Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)

Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)

Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)

Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)

Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)

Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)

McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)

Docherty, K. F. and McMurray, J. J.V. (2019) PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115(13), e136-e139. (doi: 10.1093/cvr/cvz223) (PMID:31497841)

Platz, E. et al. (2019) Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7(10), pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008) (PMID:31582107)

Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)

McMurray, J. J.V. and Docherty, K. F. (2019) Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74(7), pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008) (PMID:31416534)

Dewan, P. , Docherty, K. F. and McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)

Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)

Docherty, K. F. and McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)

Docherty, K. F. and Jhund, P. S. (2018) Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early? Heart, 104(22), pp. 1812-1813. (doi: 10.1136/heartjnl-2018-313371) (PMID:29760244)

Docherty, K. F. , Jhund, P. S. and McMurray, J. J.V. (2018) Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379(5), pp. 491-492. (doi: 10.1056/NEJMc1806519) (PMID:30070094)

Docherty, K. F. , Campbell, R. T., Jhund, P. , Petrie, M. C. and McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)

Wilson, M. R. , Docherty, K. F. and Gardner, R. S. (2016) Use of direct oral anticoagulants in thromboembolic disease. Prescriber, 27(8), pp. 15-22. (doi: 10.1002/psb.1487)

Vuorio, A., Docherty, K.F. , Humphries, S.E., Kuoppala, J. and Kovanen, P.T. (2013) Statin treatment of children with familial hypercholesterolemia – trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis, 226(2), pp. 315-320. (doi: 10.1016/j.atherosclerosis.2012.10.032)

Book Sections

Docherty, K. F. and Padmanabhan, S. (2014) Genomics and pharmacogenomics of lipid-lowering therapies. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Academic Press: London, pp. 715-746. ISBN 9780123868831 (doi: 10.1016/B978-0-12-386882-4.00031-1)

Conference or Workshop Item

Lee, M. et al. (2021) Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. ESC Congress, 27-30 Aug 2021. (doi: 10.1093/eurheartj/ehab724.1043)

This list was generated on Thu Sep 29 07:56:22 2022 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Trends in the incidence, morbidity and mortality of heart failure associated with myocardial infarction in Scotland: 1986-2016
    NHS Greater Glasgow and Clyde
    2017 - 2018